GlassScriptPhysician profile
Elaine S Date
NPI 1023107364
$3,763.47
in general payments reported to CMS, 2019-2025
33 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $853 · 2021: $232 · 2022: $482 · 2023: $159 · 2024: $142 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $727.52 | 2019-2021 | |
| Indivior INC. | $627.04 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $362.70 | 2019-2025 | Belbuca |
| Amgen INC. | $219.60 | 2019 | |
| Mdd US Operations, LLC | $202.16 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.17 | 2019-2023 | Relistor |
| Abbvie INC. | $143.52 | 2021-2024 | Botox |
| Pfizer INC. | $134.26 | 2019 | |
| Lundbeck LLC | $127.30 | 2021-2024 | Vyepti |
| Electronic Waveform Lab, INC. | $123.22 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $99.57 | 2019-2020 | |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Scilex Pharmaceuticals INC. | $83.83 | 2019-2024 | |
| Neuronetics, INC. | $80.20 | 2022 | |
| Boston Scientific Corporation | $70.02 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $66.25 | 2019-2020 | |
| Mml US, INC. | $64.62 | 2025 | Reactiv8 |
| Assertio Therapeutics, INC. | $49.36 | 2019 | |
| Averitas Pharma INC. | $32.22 | 2025 | Qutenza |
| Glaxosmithkline, LLC. | $30.33 | 2019 | |
| Relievant Medsystems, INC. | $30.17 | 2019 | |
| Avanir Pharmaceuticals, INC. | $26.84 | 2022 | |
| Flowonix Medical Incorporated | $23.36 | 2019 | |
| Nevro Corp. | $22.31 | 2019 | |
| Lilly USA, LLC | $22.11 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.50 | 2019 | |
| Janssen Biotech, INC. | $19.55 | 2019 | |
| Kaleo, INC. | $16.08 | 2019 | |
| Allergan, INC. | $15.71 | 2019 | |
| Medtronic USA, INC. | $15.56 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.61 | 2019 | |
| Biodelivery Sciences International, INC. | $12.45 | 2020 | |
| Shionogi INC | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Date listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.